Ignite Creation Date:
2025-12-24 @ 5:53 PM
Ignite Modification Date:
2025-12-28 @ 1:10 PM
Study NCT ID:
NCT00032968
Status:
COMPLETED
Last Update Posted:
2017-01-12
First Post:
2002-04-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006556', 'term': 'Heroin Dependence'}, {'id': 'D009021', 'term': 'Morphine Dependence'}, {'id': 'D013375', 'term': 'Substance Withdrawal Syndrome'}, {'id': 'D009293', 'term': 'Opioid-Related Disorders'}], 'ancestors': [{'id': 'D000079524', 'term': 'Narcotic-Related Disorders'}, {'id': 'D019966', 'term': 'Substance-Related Disorders'}, {'id': 'D064419', 'term': 'Chemically-Induced Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000069479', 'term': 'Buprenorphine, Naloxone Drug Combination'}], 'ancestors': [{'id': 'D002047', 'term': 'Buprenorphine'}, {'id': 'D009019', 'term': 'Morphinans'}, {'id': 'D053610', 'term': 'Opiate Alkaloids'}, {'id': 'D000470', 'term': 'Alkaloids'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D009270', 'term': 'Naloxone'}, {'id': 'D006572', 'term': 'Heterocyclic Compounds, Bridged-Ring'}, {'id': 'D006576', 'term': 'Heterocyclic Compounds, 4 or More Rings'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D010616', 'term': 'Phenanthrenes'}, {'id': 'D011084', 'term': 'Polycyclic Aromatic Hydrocarbons'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D004338', 'term': 'Drug Combinations'}, {'id': 'D004364', 'term': 'Pharmaceutical Preparations'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT'}, 'enrollmentInfo': {'count': 341}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2001-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2010-04', 'completionDateStruct': {'date': '2002-08', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2017-01-11', 'studyFirstSubmitDate': '2002-04-05', 'studyFirstSubmitQcDate': '2002-04-05', 'lastUpdatePostDateStruct': {'date': '2017-01-12', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2002-04-08', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2002-08', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Drug use'}, {'measure': 'Degree of drug craving'}, {'measure': 'Opiate craving'}, {'measure': 'Adverse events'}, {'measure': 'Drug craving'}, {'measure': 'Decreased frequency of HIV related behavior'}, {'measure': 'Adverse effect measures'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['opiate dependence'], 'conditions': ['Heroin Dependence', 'Morphine Dependence', 'Substance Withdrawal Syndrome']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'http://www.ctndatashare.org/protocol-ctndatashare/new-protocols/nida-ctn-0002', 'label': 'Data Elements'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to assess buprenorphine/naloxone versus clonidine for outpatient opiate detoxification.', 'detailedDescription': "Patients randomized to the BUP/NX arm will receive daily doses for 13 days with sublingual administration of 2 mg buprenorphine/0.5 mg naloxone tablet(s) and/or an 8 mg buprenorphine/2.0 mg naloxone tablet(s). The starting dose on day 1 is 4 mg/1 mg BUP/NX with an additional 4 mg/1 mg, if needed, escalating in a step-wise manner to 16 mg/4 mg BUP/NX on day 3 and tapering to 2 mg/ 0.5 mg BUP/NX by days 12 to 13. Patients randomized to the clonidine arm will receive oral clonidine (0.05 to 0.1 mg depending upon weight) every 4 to 6 hours for 24 hours not to exceed 0.6 mg total on day 1. On day 2, a clonidine transdermal patch will be applied (0.1 mg/day/7-day patch with number of patches adjusted by weight). Oral clonidine will continue to be given on the second day of detoxification and increased to 0.2 mg every 6 hours or 0.1 mg every 3 hours not to exceed 0.8 mg over 24 hours. Patches will be worn all 13 days of detoxification. The dose of clonidine will be adjusted according to the proposed detoxification schedule, patient's weight, tolerance, and systolic blood pressure. Patients will receive counseling according to procedures in existence at each CTP throughout the study. Self-help detoxification handbooks will be distributed to all study participants."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'minimumAge': '15 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Treatment-seeking males and non-pregnant and non-lactating females, 15 years and older, who fulfill DSM-IV criteria for opiate dependence, report experiencing symptoms of opiate withdrawal, are currently physically dependent on opioids and are in need of medical assistance for opioid withdrawal.\n2. Systolic blood pressure 100 mm Hg, and pulse 56 bpm.\n3. Good general health or, in case of a medical/psychiatric condition needing ongoing treatment, under the care of a physician willing to continue patient's medical management and cooperate with the study physicians.\n4. Agreeable to and capable of signing the informed consent approved by an institutional review board and, if under the age of 18 (excluding emancipated minors), assent and concurrent consent from a parent or legal guardian.\n5. Use of one of the following acceptable methods of birth control by female patients of childbearing potential:\n\n 1. oral contraceptives\n 2. barrier (diaphragm or cervical cap) with spermicide or condom\n 3. intrauterine progesterone contraceptive system\n 4. levonorgestrel implant\n 5. medroxyprogesterone acetate contraceptive injection\n 6. complete abstinence from sexual intercourse\n\nExclusion Criteria:\n\n1. Medical condition that would make participation, in the opinion of the study physician, medically hazardous (e.g., acute hepatitis, unstable cardiovascular, liver or renal disease);\n2. Clinically significant abnormalities in ECG.\n3. Known allergy or sensitivity to buprenorphine, naloxone, or clonidine.\n4. Receiving beta-blockers, calcium channel blockers, tricyclics, digitalis and other medications which may interact adversely with clonidine.\n5. Acute severe psychiatric condition in need of immediate treatment, or imminent suicide risk.\n6. Dependence on alcohol, benzodiazepines or other depressants, or stimulants, and requiring immediate medical attention.\n7. Participation in an investigational drug study, including buprenorphine, within the past 30 days.\n8. Methadone or LAAM maintenance or detoxification within 30 days of enrollment.\n9. Pending legal action that could prohibit or interfere with participation.\n10. Unable to remain in area for duration of active phase of treatment.\n11. Females that are pregnant, lactating, or planning to become pregnant."}, 'identificationModule': {'nctId': 'NCT00032968', 'briefTitle': 'Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1', 'nctIdAliases': ['NCT00016757'], 'organization': {'class': 'NIH', 'fullName': 'National Institute on Drug Abuse (NIDA)'}, 'officialTitle': 'Buprenorphine/Naloxone Versus Clonidine For Out-patient Opiate Detoxification', 'orgStudyIdInfo': {'id': 'NIDA-CTN-0002-1'}}, 'armsInterventionsModule': {'interventions': [{'name': 'Buprenorphine/naloxone', 'type': 'DRUG'}]}, 'contactsLocationsModule': {'locations': [{'zip': '94704', 'city': 'Berkeley', 'state': 'California', 'country': 'United States', 'facility': 'Haight-Ashbury Free Clinic', 'geoPoint': {'lat': 37.87159, 'lon': -122.27275}}, {'zip': '93033', 'city': 'Oxnard', 'state': 'California', 'country': 'United States', 'facility': 'Aegis Medical Systems, Inc.', 'geoPoint': {'lat': 34.1975, 'lon': -119.17705}}, {'zip': '46202', 'city': 'Indianapolis', 'state': 'Indiana', 'country': 'United States', 'facility': 'Midtown Community Mental Health Center', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'zip': '08854', 'city': 'Piscataway', 'state': 'New Jersey', 'country': 'United States', 'facility': 'UMDNJ - Robert Wood Johnson Medical School', 'geoPoint': {'lat': 40.49927, 'lon': -74.39904}}, {'zip': '11201', 'city': 'Brooklyn', 'state': 'New York', 'country': 'United States', 'facility': 'Addiction Research and Treatment Corp', 'geoPoint': {'lat': 40.6501, 'lon': -73.94958}}, {'zip': '10016', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Bellevue', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '97227', 'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Kaiser Permanente Northwest, Division of Addiction', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}], 'overallOfficials': [{'name': 'Walter Ling, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Los Angeles Treatment Research Center'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University of California, Los Angeles', 'class': 'OTHER'}, 'responsibleParty': {'oldNameTitle': 'Walter Ling, M.D.', 'oldOrganization': 'University of California, Los Angeles'}}}}